Once-versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 4, 2012, Pages 495-500

  Wang, Yadan ^a   Ai, Lisha ^a   Cui, Guohui ^a   Gowrea, Bhuveshwarnath ^a   Li, Mian ^a   Hu, Yu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adverse event; Bortezomib; Multiple myeloma; Response rate; Weekly schedule

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

ADULT; AGED; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 84865644839     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-0086-7     Document Type: Article

References (27)

1. Richardson PG, Mitsiades C, Hideshima T, et al. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med, 2006,57:33-47
2. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol, 2011,154(1):32-75
3. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma, 2009,9(4):278-288
4. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Clin Oncol, 2010,28(30):4621-4629
5. Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw, 2009,7(9):908-942
6. Offidani M, Corvatta L, Polloni C, et al. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Ann Hematol, 2011,90(12):1449-1456
7. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med, 2008,359(9): 906-917
8. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol, 2010,28(13): 2259-2266
9. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term followup. Br J Haematol, 2008,141(4):512-516
10. Zheng W, Wei G, Ye X, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leuke Res, 2009,33(12):1615-1618
11. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol, 2004,22 (11):2108-2121
12. deVos S. Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study. Blood ASH Annual Meeting, 2005,106:10a
13. Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer, 2008,113(4): 765-771
14. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia, 2006,20(9):1467-1473
15. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006.
16. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibiliy of peripheral neuropathy during Treatment of advanced multiple myeloma with Bortezomib. J Clin Oncol, 2006,24(19):3113-3120
17. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res, 1999,59(11):2615-2622
18. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature, 2003,426(6968): 895-899
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 2002,20(22):4420-4427
20. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 2010,95(2):311-319
21. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol, 2009,144(6):895-903
22. Suvannasankha A, Smith GG, Juliar BE, et al. Weekly bortezomib/ methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma, 2006,7(2):131-134
23. Tokuhira M, Watanabe R, Nemoto T, et al. Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leuk Res, 2011,35(5):591-597
24. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, 116(23):4745-4753
25. Munshi N C, Lee S, Kambhampati S, et al. Interim results of an ongoing clinical study suggests efficacy and improved toxicity profile with once a week bortezomib with dexamethasone in newly diagnosed multiple myeloma patients with older age and co-morbidities. Blood ASH Annual Meeting, 2010,116:Abstract 3061
26. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy inmultiplemyeloma: a comprehensive review of the literature. Blood, 2008,112(5):1593-1599
27. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol, 2010,151(4):346-353